Literature DB >> 7333058

Binding and displacement of basic, acidic and neutral drugs in normal and orosomucoid-deficient plasma.

E Pike, B Skuterud, P Kierulf, D Fremstad, S M Abdel Sayed, P K Lunde.   

Abstract

The binding of the basic drugs quinidine, propranolol and amitriptyline, the neutral drug digitoxin and the acidic drug phenytoin to heparinised normal plasma, to orosomucoid (alpha 1-acid glycoprotein)-deficient plasma and to purified orosomucoid and albumin was studied in both the presence and absence of tris (2-butoxyethyl)-phosphate (TBEP) and de-(2-ethylhexyl)-phthalate (DEHP). The addition of TBEP and DEHP to heparinised plasma in concentrations up to 2.5 mmol/L markedly increased the unbound fractions of quinidine and propranolol, but the increase was less for amitiriptyline, TBEP being the most potent displacer. In orosomucoid-deficient plasma, which was prepared by immunoprecipitation, the free fraction of quinidine was similar to that of normal plasma in which maximal displacement with TBEP was obtained. The addition of the displacers to orosomucoid-deficient plasma caused no further reduction in the binding, nor was the plasma binding of digitoxin and phenytoin significantly affected. When combining purified albumin and orosomucoid in concentrations found in normal plasma, quinidine binding approached that of heparinised normal plasma. This study confirms the dominant role of orosomucoid in the variable plasma binding of basic drugs, and underlines the value of using immunologically prepared orosomucoid-deficient plasma and TBEP or DEHP as model displacers.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7333058     DOI: 10.2165/00003088-198106050-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  17 in total

1.  Spuriously low plasma propranolol concentrations resulting from blood collection methods.

Authors:  R H Cotham; D Shand
Journal:  Clin Pharmacol Ther       Date:  1975-11       Impact factor: 6.875

2.  DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS.

Authors:  B J DAVIS
Journal:  Ann N Y Acad Sci       Date:  1964-12-28       Impact factor: 5.691

3.  Plasma protein binding of drugs as influenced by blood collection methods.

Authors:  D Fremstad; K Bergerud
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1976

Review 4.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

5.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors:  M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

6.  Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution.

Authors:  P K Lunde; A Rane; S J Yaffe; L Lund; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1970 Nov-Dec       Impact factor: 6.875

7.  Abnormal pharmacokinetics of phenytoin in a patient with uraemia.

Authors:  I Odar-Cederlöf; P Lunde; F Sjöqvist
Journal:  Lancet       Date:  1970-10-17       Impact factor: 79.321

8.  Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants.

Authors:  A Rane; P K Lunde; B Jalling; S J Yaffe; F Sjöqvist
Journal:  J Pediatr       Date:  1971-05       Impact factor: 4.406

9.  Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs.

Authors:  E M Sellers; J Koch-Weser
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

10.  Increased plasma binding of quinidine after surgery: a preliminary report.

Authors:  D Fremstad; K Bergerud; J F Haffner; P K Lunde
Journal:  Eur J Clin Pharmacol       Date:  1976       Impact factor: 2.953

View more
  9 in total

1.  Pharmacokinetics of quinidine in male patients. A population analysis.

Authors:  C N Verme; T M Ludden; W A Clementi; S C Harris
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

2.  The binding of ketamine to plasma proteins: emphasis on human plasma.

Authors:  P G Dayton; R L Stiller; D R Cook; J M Perel
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Plasma protein binding of imipramine in patients with rheumatoid arthritis.

Authors:  C B Kristensen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Pharmacokinetics of lidocaine in children with congenital heart disease.

Authors:  F A Burrows; J Lerman; K M LeDez; H A Strong
Journal:  Can J Anaesth       Date:  1991-03       Impact factor: 5.063

5.  Alpha 1-acid glycoprotein and the binding of lidocaine in children with congenital heart disease.

Authors:  F A Burrows; J Lerman; K M LeDez; H A Strong
Journal:  Can J Anaesth       Date:  1990-11       Impact factor: 5.063

Review 6.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

7.  Serum alpha 1-acid glycoprotein and the binding of drugs in obesity.

Authors:  I H Benedek; W D Fiske; W O Griffen; R M Bell; R A Blouin; P J McNamara
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

8.  Mianserin protein binding in serum and plasma from healthy subjects and patients with depression and rheumatoid arthritis.

Authors:  C B Kristensen; L F Gram; P Kragh-Sørensen
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

9.  The in vitro serum protein-binding characteristics of bis-(2-ethylhexyl) phthalate and its principal metabolite, mono-(2-ethylhexyl) phthalate.

Authors:  W C Griffiths; P D Camara; A Saritelli; J Gentile
Journal:  Environ Health Perspect       Date:  1988-04       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.